Recent advances in exacerbations of COPD

Terence Seemungal,1 Annemarie Sykes,2 and the ICEAD Contributors

The First International Conference on Exacerbations of Airways Disease (ICEAD) brought together experts from both sides of the Atlantic to discuss problems in the management of exacerbations of both asthma and chronic obstructive pulmonary disease (COPD). A brief overview of these discussions on COPD exacerbations follows.

DEFINITIONS AND EPIDEMIOLOGY
Symptom and treatment based definitions
Up to 18 definitions of a COPD exacerbation have been advanced, from less explicit1 to very explicit symptom based criteria.2,3 However, large therapeutic trials in COPD have all used treatment based definitions.4,5 The first consensus definition was treatment based but the current GOLD guidelines accept a symptom based definition.6 Biochemical or physiological markers applied in studies using either definition7,8 have all shown significant changes, supporting the validity of these approaches to a definition but lack specificity and sensitivity. The healthcare utilisation approach to severity of exacerbation may be more robust as it has been related to mortality9 but does not allow for detection of untreated exacerbations, which may contribute to poor quality of life.

Health burden
COPD patients have about 0.5–3.5 exacerbations/year, 0.09–2.4 hospitalisations/year and inhospital mortality varies between 10% and 60%, depending on the severity of COPD. Overall, the death rate varies from 5.4 per 1000 person years among normal subjects to 42.9 among subjects with GOLD stage 3 or 4.11 Thus COPD exacerbations are a significant cause of death, mainly in patients with more severe COPD. This leads to a high cost of COPD care which can be effectively reduced through decreasing hospitalisation.12

AETIOLOGY AND SUSCEPTIBILITY
Airway bacterial infection
Bacteria may be detected in up to 60% of exacerbations and viruses in 25–60%.12,13 However, large therapeutic trials in COPD have all used treatment based definitions.13,14 The acquisition of new strains of bacteria is associated with an increased risk of COPD exacerbation, more inflammation and strain specific immunity.15,16 However, non-specific reduction of bacterial load during recovery from COPD exacerbation has been associated with resolution of inflammation.9 Viruses and coinfection
Respiratory viruses have been associated with higher exacerbation sputum interleukin (IL)-6 levels, with prolonged COPD exacerbations and significant health burden.13,17,18 Furthermore, bacteria–virus coinfection leads to greater lung impairment and longer inhospital stay.14 Susceptibility and inflammation
Frequent COPD exacerbators appear to be a distinct phenotype characterised by a faster decline in lung function, poorer quality of life scores, more viruses at exacerbation, higher mortality, greater airway inflammation and higher airway bacterial load.3,5,10,13,19 Frequent exacerbators also have smaller reductions in systemic inflammation post-exacerbation further. Interestingly, a high serum C reactive protein concentration post-exacerbation is associated with recurrence.20 Susceptibility and other factors
Viruses detected in lower airway samples of patients with stable COPD affect systemic inflammatory processes as well as lower airway bacterial load.13,21 Thus it is likely that the susceptibility of the frequent exacerbator phenotype is associated with viral colonisation of the lower airway although this has yet to be proved.

REFERENCE
Other factors that may affect susceptibility are upper airway inflammation and bacterial colonisation, previous infection with non-typeable *Haemophilus influenzae*, season and environmental temperature.22 23

PATHOGENESIS

Pathophysiology

The acute and variable increase in end expiratory lung volume above its stable baseline is termed dynamic hyperinflation and occurs during COPD exacerbations.24 This leads to falls in spirometric parameters and increased functional residual capacity and residual volume. The resulting increased loading and functional weakness of the respiratory muscles may prevent a response to increased neural drive and thus neuromechanical uncoupling of the respiratory system occurs. This dissociation in response to acute dynamic hyperinflation is thought to contribute to the sensation of dyspnoea during COPD exacerbations.24

Cell mediated mechanisms

Both eosinophils and neutrophils are recruited during COPD exacerbations.14 25 Bacterial infection has been related to neutrophil chemotactant gene expression which is upregulated during COPD exacerbation.16 26

Amplification of inflammation at COPD exacerbation

The amplification of airway and mucosal inflammation at COPD exacerbation is thought to be due to activity along two pathways involving (a) nuclear factor κB (NFκB) translocation, which involves NFκB inducing kinase 2 (IKK2) and (b) mitogen activated protein kinase-p38 (p38-MAPK).27 These pathways are upregulated at COPD exacerbation28 and in the presence of non-typeable *Haemophilus influenzae*.29

Oxidative stress at COPD exacerbation

Compared with normal subjects, histone deacetylase (HDAC) activity is reduced in COPD and this reduction increases with increasing COPD severity and is associated with increased basal release of IL8 and tumour necrosis factor α (TNFα) that is poorly suppressed by dexamethasone thus indicating an association with steroid resistance in patients with COPD.29 30 Pro-oxidants are elevated during COPD exacerbation.31 Nitric oxide, for example, combines with superoxide anions to form peroxynitrite that in turn leads to nitration (and thus further inactivation) of HDAC2 and proteasome degradation, leading to amplification of the inflammatory cascade.

EXPERIMENTAL TECHNIQUES AND CLINICAL TRIAL STRATEGIES

Experimental models

Krug et al have advanced a lipopolysaccharide (LPS) challenge model of a COPD exacerbation that is safe with no significant effects on mean arterial pressure or heart rate. Using the model, instillation of LPS into a bronchopulmonary segment induces an inflammatory response similar to a COPD exacerbation. This model responds to treatment with anti-monocytes chemotactic protein 1 and to phosphodiesterase 4 inhibition.32 33

Clinical trials

A health care utilisation approach to staging is health system specific and affected by other factors such as social support and patient affect as well as baseline health status and comorbidities which are not taken into account in the definition. Because of a variable recovery time which may depend on aetiology, the baseline of stability is difficult to determine for clinical studies.34

Markers of COPD exacerbation

Often, questionnaires have been designed by clinicians, and this has been found to lack primary validity by the Food and Drug Administration (FDA) in the USA. The FDA, however, is working with other bodies to develop a patient reported outcome tool to measure acute exacerbations. The patient identified attributes of exacerbations have been: cough, sputum, dyspnoea and chest discomfort, activity limitation, malaise, anxiety and sleep disturbance. It is believed that each of these attributes has a different time course. Unlike patient centred attributes, a biomarker is free from subjectivity but may be assay dependent.

CURRENT AND FUTURE THERAPY

How good is current therapy?

Systemic steroids used at exacerbation lead to a faster recovery rate in lung function and symptoms, and are associated with a decreased relapse rate compared with placebo24 35 but are associated with hyperglycaemia,36 invasive aspergillosis and steroid psychosis.37 A meta-analysis of antibiotics for acute exacerbations showed that secondline (newer) antibiotics are associated with greater “treatment success”38 and are not less safe when administered to patients at exacerbation than frontline agents. Systematic analyses show that antibiotics and systemic steroids decrease treatment failures within 30 days but only antibiotics improve mortality.37 38 Nevertheless, the mortality and hospitalisation rates following COPD exacerbations suggest that current treatment is still not optimal.

Modifications of current therapy

Long acting β2 agonists may find increasing use as rescue therapy: formoterol and indacaterol as inhalers and arformoterol (R, R-formoterol) in nebulised form. Formoterol is being combined with several other inhaled steroids as has been done in asthma treatment. The long acting antimuscarinic, aclidinium, may also be useful as rescue therapy. Some anti-infective agents have importance in treating COPD exacerbations and these include antimicrobial peptides, new antiviral drugs which target unique viral genes and toll-like receptor antagonists.

Theophylline activates HDAC via a novel mechanism and restores HDAC activity in alveolar macrophages from patients with COPD.29 39 Macrolides have anti-inflammatory activity and are effective in cystic fibrosis and diffuse panbronchiolitis.40 Both of these agents appear to potentiate the effects of steroids and thus different combinations of well known drugs may be more useful than current combinations.

New anti-inflammatory drugs

Phosphodiesterase inhibitors have been shown to inhibit the formation of reactive oxygen species and leukotriene B4 synthesis in vitro.41 Because of their systemic side effects, their use may require inhaled administration. Blockade of the NFκB pathway by an IKK2 inhibitor is associated with decreased granulocyte macrophage colony stimulating factor production and inhibition of p38-MAPK decreases luciferase activity in response to TNFα/non-typeable *Haemophilus influenzae*.32 42 Leukotriene B4 and IL8 antagonists have been shown to inhibit neutrophil chemotaxis,43 and combined blockade of the neutrophil chemokine receptors CXCR1 and CXCR2 slows LPS induced neutrophil migration. Most of these newer agents have yet to be tested in clinical trials.

Future directions

A definition based on prolonged deterioration in chronic symptoms is useful but subjective. A surrogate marker of a COPD exacerbation would be of interest but such a marker should have reproducibility,
sensitivity to change and the clinically minimally important change in the marker must be known. Reducing hospitalisation rates through strategies to prevent COPD exacerbations may reduce the high health burden in COPD.

Further work must be done on the interaction between viruses and bacteria: does viral infection trigger the shift in strain of colonising bacteria seen during COPD exacerbations or is the effect mainly on bacterial load? Viruses are related to increased dyspnoea at exacerbation and thus an infective agent may be related to dynamic hyperinflation and hence to exacerbation severity. Frequent exacerbations are a marker of host susceptibility to exacerbation. Both pro-oxidants and chemokines cause inflammation through pathways mediated by NFκB. Blockade of steps along this pathway may be useful in attenuating the inflammatory response to infection. In the future, we may have to treat COPD exacerbations using receptor specific inhibitors along the inflammatory pathway.

Acknowledgements: Based on presentations at the first International Congress on Exacerbations of Airway Disease (ICEAD) Puerto Rico, 4–7 October 2007.

Competing interests: None.

A list of the International Congress on Exacerbations of Airway Disease (ICEAD) contributors is published online only at http://thorax.bmj.com/content/vol63/issue10


REFERENCES


Recent advances in exacerbations of COPD

Terence Seemungal, Annmarie Sykes and the ICEAD Contributors

*Thorax* 2008 63: 850-852
doi: 10.1136/thx.2008.099127

Updated information and services can be found at:
http://thorax.bmj.com/content/63/10/850

These include:

**References**
This article cites 39 articles, 13 of which you can access for free at:
http://thorax.bmj.com/content/63/10/850#BibL

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Topic Collections**
Articles on similar topics can be found in the following collections

*Inflammation* (1020)
*Epidemiologic studies* (1829)
*Therapeutic trials* (13)
*Drugs: infectious diseases* (968)
*Asthma* (1782)

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/